Introduction
Occlusive peripheral vascular disease is a common cause of morbidity in the USA and other industrialized nations. Although estimates vary, recent evidence suggests that the prevalence may be as high as 25% for men and women of advanced age. t -S As with coronary atherosclerotic disease, the prevalence increases with age, and in a sizeable number of individuals it progresses steadily over time resulting in loss of mobility, gangrene, or amputation." From a socioeconomic perspective, occlusive peripheral vascular disease is a major cause of days lost from work and is responsible for billions of dollars in health care costs.
Epidemiological studies have firmly demonstrated a strong association between cigarette smoking and the development, progression and morbidity of peripheral vascular disease." Other risk factors include diabetes mellitus, systemic hypertension, hypercholesterolaemia and possibly postmenopausal status in women.s-?
Although a majority of patients with peripheral vascular disease and intermittent claudication can be treated conservatively, as existing disease progresses functional status and limb viability may © Edward Arnold 1995 be compromised and jeopardized, respectively. In this setting, more aggressive pharmacological, mechanical, or surgical intervention is warranted.
The following review will focus on novel adjunctive pharmacological therapy for patients with advanc~d occlusive peripheral vasc~lar disease, addressing those drugs currently 10 the early stages of preclinical/clinicalstudies.
Anticoagulants

Hirudin
In 1884, John B Haycraft identified an anticoagulant substance contained within medicinal leeches (Hirudo medicinalisy.w Original attempts to isolate the active agent were unsuccessful; however, in the late 1950s, hirudin was isolated by Markwardt and colleagues.11.12 Recombinant hirudin, nearly identical to natural hirudin variant 1 except for the lack of a sulphate group on Tyr-63, is a 65 amino acid peptide of nearly 10 000 Da. It is a highly potent selective inhibitor of thrombin, a pivotal enzyme involved in the conversion of fibrinogen to fibrin, prothrombinase generation, and platelet aggregation. The tight and essentially irreversible binding of hirudin to thrombin is achieved by interactions occurring both at the active site of thrombin and at the fibrinogen recognition site (anion-binding exosite).
A highly purified recombinant hirudin has recently beenproduced in sufficient quantity for experimental and clinical use. 13 , 14 Currently, several large-scale clinical trials including patients with acute coronary syndromes are in progress. Its half-life is between two and three hours and clearance is predominantly by the renal route. Hirudin can be administered either intravenously or subcutaneously. 15, 16 Hirulog A 20 amino acid synthetic peptide designed on the basis of structural studies with hirudin, hirulog contains two domains: (1) a carboxyterminal domain that binds to the fibrinogen (and platelet receptor site) of thrornbin.!? and (2) a catalytic site inhibitor domain. These two domains are joined by a 'linker' region with optimal length to allow potent thrombin inhibition at both sites. Hirulog binds reversibly with thrombin in a 1:1 relation with binding characteristics consistent with competitive inhibition. 18, 19 Hirulog differs from hirudin in several ways. First, it is a smaller peptide. Second, hirudin binds directly to the thrombin active site via the d-Phe-Pro-Arg-Pro sequence in a substrate-like fashion, whereas hirudin binds to the active site with a divergent, unique orientation. The half-life of hirulog is approximately 40 minutes.w Several clinical trials involving patients with atherosclerotic coronary artery disease l 7 ,2 1 and those undergoing coronary angioplasty have been performed.F Major, multicentre studies are also in progress.
Tick anticoagulant peptide
Tick anticoagulant peptide is a potent inhibitor of coagulation factor Xa, a pivotal enzyme in the common coagulation pathway. A recombinant form of a 60 amino acid polypeptide originally isolated from the tick Ornithodoros moubata is available and has been shown in a baboon dacron graft thrombosis model to reduce platelet and fibrin deposition. 23 ,24 Antistatin A potent and selective inhibitor of factor Xa, antistatin was isolated originally from the Mexican leech Aaementeria officinalis. 25 It binds factor Xa tightly both in solution and in plasma, and may be administered either subcutaneously or intrave-nously. The clinical use of antistatin may be limited, however, by its antigenicity.
Tissue factor pathway inhibitor
Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor that has been shown in vitro to effectively inhibit factor VIIa:tissue factor catalytic activity (extrinsic coagulation pathway). Interestingly, this inhibition is a two-step feedback reaction. In the first step, factor Xa:TFPI complex binds to and inhibits the catalytic activity of factor VlIa:tissue factor complexes. 26 ,27 Anti-tissue factor monoclonal antibodies have also been developed.se
Low molecular weight heparin"
The development of low molecular weight heparin fractions was prompted by the OCcurre.nce of ad~erse reaction~(p.rimarily bleeding) with unfractionated hepann, mtroducing a new dimension to the prevention and treatment of thromboembolic diseases.
Low molecular weight heparins are prepared fron:t standard. heparin by fractionation, enzymane degradation, or chemical modification. As a group, their mean molecular weight varies from 32~to 65~..Characteristically, they contain high anti-Xa activity and low antithrombin activity. As a result, both the intrinsic and extrinsic coagulation pathways are inhibited. Although it was origin~lly anucipated that low molecular weight hepann pre~aratlOns would cause less bleeding than unfractionatsd heparin, increasing clinical expenence has not yet borne this out. They do, however, have the advantage of being almost completely absorbed folIowing subcutaneous administration, allowing for once a day dosing in many instances.
At the present time, low molecular weight heparin preparations represent an anticoagulant alternative that is at least as safe and effective in the treatment of deep vein thrombosis as standard (unfractionated) heparin. 2 9-31 The advantage of once daily subcutaneous dosing may translate into greater wide-scale applicability and home use (in select cases).
• Editor's note: Low molecular weight heparins will be the subject ofa major review in Volume 6, Number 4.
Antiplatelet agents
For more than a century, platelets have been recognized as a major component of normal physiological haemostasis, providing a first line of defence after vascular trauma. More recently, however, their central role in the regulation of coagulation protein interactions, fibrinolytic processes, vascular endothelial cell function, atherogenesis and thrombogenesis has been appreciated.
The participation of platelets in the thrombotic process is determined by their ability to adhere to an abnormal (damaged or dysfunctional) vascular Surface, aggregate to form a template (platel~t plug) for subsequent thrombus growth, and activate, thus stimulating further platelet aggregation and initiation of the coagulation cascade. To date, aspirin has been the best studied, but other novel agents are now becoming available.
Antibodies to factor VIII von Willebrand factor (vWF)
In areas of vascular narrowing caused by an underlying atheroma, plaque rupture, or haemorrhage, platelet adhesion and aggregation are mediated by vWF and also the platelet receptors GP IE and GP Ilb/Illa. Monoclonal antibodies to vwpz and aurintricarboxylic acid.P a triphenylmethyl dye compound, inhibit platelets in regions of high-shear stress through their competitive binding to vWF, thus preventing its interaction with platelet receptors and damaged or dysfunctional vessel walls.
GP IIb/I1a receptor blockers
The platelet GP lIb/IIa receptor, a member of the integrin family of receptors, is unique in two ways. First, normal platelets have a large number of receptors (50000) on their surface. Secondly, platelet activation exposes additional receptor sites. In essence, all physiological platelet agonists act by exposing the GP lIb/IlIa receptor.
Monoclonal antibodies to the GP IIb/IIIa receptor have been developed recently. The F(ab)z fragment of this antibody can completely block in vitro platelet aggregation that is induced by agonists thought to function in vivo. 34 Largescale clinical trials, predominantly in patients with coronary artery disease, are in progress.
The ability of GP Ilb/Illa to bind a number
Advanced occlusive peripheralvascular disease 171 of naturally occurring substances has been explained, at least in part, by the fact that it contains a binding site for the tripeptide Arg-Gly-Asp. All substances that bind to the GP lIb/IlIa receptor contain this amino acid sequence; therefore, synthetic compounds that contain the Arg-Gly-Asp (RGD) sequence (e.g. Integrilin) can competitively inhibit the binding of fibrinogen to GP lIb/IlIa. 35 
Ticlopidine
Ticlopidine hydrochloride is structurally distinct from all other antiplatelet agents. It is a potent inhibitor of platelet aggregation induced by ADP, and it variably inhibits aggregation medicated by collagen, epinephrine, arachidonic acid, thrombin and platelet activating factor. Ticlopidine also inhibits the platelet release reaction and may impair platelet adhesion as well.w
Thromboxane and endoperoxide receptors
Drugs that inhibit thromboxane synthetase, such as dazoxiben and Pirmagrel, have been developed to suppress platelet thromboxane A 2 synthesis, thereby preventing platelet aggregation. 37 ,38 Despite their theoretical potential, currently available agents are limited by two factors: (1) incomplete thromboxane A 2 inhibition, and (2) the aggregation potential of endoperoxide intermediates.
The potential limitations of thromboxane synthetase inhibitors can, at least theoretically, be managed by inhibiting the receptors for both thromboxane A 2 and the active endoperoxide intermediates. In addition to inhibiting platelet aggregation, the vasoactive effects of thromboxane A z can also be blocked.a? Several compounds are undergoing clinical investigation. One in particular, Ifetroban (a thromboxane receptor antagonist), is being assessed in a series of phase II studies including patients with coronary artery disease.
Omega-S fatty acids
The n-3 class of polyunsaturated fatty acids, particularly eicosapentaenoic acid, may be valuable in preventing the thrombotic complications of cardiovascular disease.s? Omega-3 fatty acid supplementation decreases the platelet membrane concentration of arachidonic acid, thus preventing thromboxane A 2 synthesis. In addi-tion, eicosapentaenoic and docosahexaenoic acids compete with arachidonic acid for cyclooxygenase, leading to the formation of three biologically inactive prostanoids -prostaglandin G a , prostaglandin H 3 and thromboxane A 3 • Within vascular endothelial cells, however, n-3 fatty acids are responsible for the synthesis of prostaglandin la' a potent platelet inhibitor.st-s? Studies ofthese compounds are under way in patients with diabetic vascular disease and in claudicants following peripheral argioplasty.
Agents that inhibit growth factors
Platelet-derived growth factor (PDGF) is a potent mitogen and chemoattractant that is capable of stimulating smooth muscle cell and fibroblast proliferation in tissue culture.P The in vitro and in vivo stimulatory effect of PDGF is significantly reduced by triazolopyridine (trapidil), a biazol pyrimidine derivative that also has vasodilatory and cholesterol-lowering properties. 44 
Concluding statement
The impact of adjunctive strategies on overall vascular events must be recognized. In addition to being the preferred approach to maintaining peripheral vessel patency, antiplatelet therapy (predominantly with aspirin or ticlopidine) has been shown conclusively to reduce vascular death, nonfatal myocardial infarction, and stroke. 45 • 46 . A wide and diverse array of anticoagulants and platelet antagonists have been developed and investigated among patients with vascular disease. To date, their benefits have been studied most extensively in the coronary artery arena. In the future greater exploration must be undertaken to include patients with peripheral vascular disease. Br MedJ 1994; 308: 81-106.
